- Home
- SITC vs CSTL Comparison
SITC vs CSTL Comparison
Compare SITC & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SITC
- CSTL
- Stock Information
- Founded
- SITC 1965
- CSTL 2007
- Country
- SITC United States
- CSTL United States
- Employees
- SITC N/A
- CSTL N/A
- Industry
- SITC Real Estate Investment Trusts
- CSTL Medical Specialities
- Sector
- SITC Real Estate
- CSTL Health Care
- Exchange
- SITC Nasdaq
- CSTL Nasdaq
- Market Cap
- SITC 600.0M
- CSTL 555.8M
- IPO Year
- SITC 1993
- CSTL 2019
- Fundamental
- Price
- SITC $12.21
- CSTL $20.84
- Analyst Decision
- SITC Hold
- CSTL Strong Buy
- Analyst Count
- SITC 8
- CSTL 6
- Target Price
- SITC $35.25
- CSTL $37.67
- AVG Volume (30 Days)
- SITC 1.1M
- CSTL 698.8K
- Earning Date
- SITC 08-05-2025
- CSTL 08-04-2025
- Dividend Yield
- SITC 38.97%
- CSTL N/A
- EPS Growth
- SITC N/A
- CSTL N/A
- EPS
- SITC 6.74
- CSTL N/A
- Revenue
- SITC $173,351,000.00
- CSTL $346,269,000.00
- Revenue This Year
- SITC N/A
- CSTL N/A
- Revenue Next Year
- SITC $5.90
- CSTL $1.62
- P/E Ratio
- SITC $1.70
- CSTL N/A
- Revenue Growth
- SITC N/A
- CSTL 20.40
- 52 Week Low
- SITC $10.46
- CSTL $14.59
- 52 Week High
- SITC $18.15
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- SITC 63.23
- CSTL 64.07
- Support Level
- SITC $11.39
- CSTL $19.23
- Resistance Level
- SITC $12.06
- CSTL $20.80
- Average True Range (ATR)
- SITC 0.28
- CSTL 1.01
- MACD
- SITC 0.10
- CSTL 0.21
- Stochastic Oscillator
- SITC 99.54
- CSTL 81.42
About SITC SITE Centers Corp.
SITE Centers Corp is a self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing and managing shopping centers.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.